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A portion of melanoma is familial and has been asso­
ciated with atypical mole syndrome. This review out­
lines the current understanding of the genetics of mel­
anoma and the relationship to cutaneous nevus 
phenotypes. A review of genetic studies of melanoma is 
presented, including linkage studies. Data from a link­
age study of 12 Utah kindreds and one Texas kindred 
are detailed. 
There is strong evidence both for a genetic compo­
nent to melanoma and, to a lesser extent, for a genetic 
component to the atypical mole phenotype. Reports of 
linkage of melanoma/dysplastic nevus syndrome to 
chromosome Ip markers are now strongly in doubt. 
The Utah group has shown strong evidence of linkage 
T here is strong evidence that melanoma has a familial and a genetic component [1.2]. Since the late 1970s, most research on the genetics of melanoma has fo­cused on its association with an atypical pattern of moles, now commonly known as the dysplastic nevus 
syndrome [3-6]. Genetic studies using the combined cutaneous 
melanoma-dysplastic nevus syndrome trait have been highly con­
troversial. We have recently localized a melanoma risk allele to the 
chromosomal region 9p21 using invasive melanoma as the clinical 
manifestation of the susceptibility locus [7]. This review discusses 
the evidence for a specific melanoma susceptibility locus and the 
different methods of clinical, epidemiologic, and genetic analysis 
used in the studies of melanoma and nevi. 
HISTORY 
The clinical observation of &milies having an excess of melanoma 
was first made in 1951 by Cawley [1]. He described several kindreds 
where multiple rust degree relatives had cutaneous melanoma. 
Throughout the 1950s and 1960s occasional case reports or small 
series of families with multiple members who had melanoma ap­
peared in the literature. In 1971, Anderson estimated that approxi­
matel;: 10% of all melanoma was due to a specific familial associa­
tion l2]. This estimate, based on clinical observation, is still in 
common usage in the medical literature. 
A population-based assessment of the &miliality of cancer by site 
was performed by Cannon et al [8]. This analysis showed that mela­
noma cases were more closely related and showed closer familial 
clustering than most other cancer sites, including colon cancer and 
breast cancer, which have been long recognized to have a familial 
component, and for which susceptibility loci have been mapped 
(Table I). 
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of melanoma to chromosome 9p21 without evidence 
for heterogeneity. This is in the same region where 
chromosomal deletions are common in tumors of nu­
merous tissues. 
We conclude that there is a specific melanoma sus­
ceptibility locus located on chromosome 9p. The com­
bination of the results of linkage in families with mul­
tiple cases of melanoma and the deletion of this 
chromosomal region in sporadic cases of melanoma 
strongly suggests that this melanoma susceptibility 
locus acts as a tumor suppressor. Key words: nevru/ 
linkage/tumor suppressor. J Invest Dermatol 103:1128-
1168,1994 
MELANOMA AND NEVI 
Genetic studies using a combined melanoma-dysplastic nevus syn­
drome trait have been highly controversial. Because the genetics of 
melanoma has largely been intertwined with the study of nevi, it is 
necessary to review the relationship of nevi to melanoma. 
Recently an NIH consensus panel focusing on early melanoma 
has suggested dropping the term dysplastic nevus, due to problems 
of definition [9]. In some previous reports, dysplastic nevi were 
diagnosed clinically [10] (although dysplastic is a histopathologic 
term) and differing histologic criteria for dysplasia have been used in 
other studies. In most studies, absence of dysplasia has been evalu­
ated by clinical examination only. Similar problems exist with diag­
nosis of the dysplastic nevus syndrome, often based on clinical or 
histologic criteria [11]. In this discussion the terms dysplastic nevus 
syndrome and dysplastic nevus are used for historical refer­
ence only. We prefer the terms clinically atypical nevus, nevus 
with architectural and/or cytologic atypia, and atypical mole syn­
drome. 
There are several types of associations between nevi and mela­
noma. First, there is an obvious association in that they are a related 
cell type. There is also the clinical observation that melanoma may 
evolve from various types of nevi [6]. Estimates of the percentage of 
melanomas that arise from nevi vary widely. Some binilies with a 
high incidence of melanoma also have an abnormal clinical nevus 
phenotype, discussed below [6]' Finally. case-control studies have 
demonstrated an association of excess number of nevi and clinically 
atypical and/or histologically dysplastic nevi with melanoma risk in 
multiple ethnic groups on multiple continents [12-15]. 
, .. 'The dysplastic nevus syndrome (DNS) was rust described in 1978 
. and was termed BK mole syndrome [3,5] or familial atypical multi­
ple mole melanoma syndrome [4]. Since those initial descriptions, 
most genetic studies of melanoma have incorporated some measure 
of nevus phenotype, often considering the atypical mole to be a 
premalignant lesion which might be expressed in gene carriers prior 
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Table I. Sixteen Common Cancers Ranked By Degree of Kinship' 
Rank 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Cancer Site 
Lip 
Melanoma 
Ovary 
Prostate 
Colon 
Rectal/Anal 
.Breast (male & female) 
Hematopoietic 
.Brain/CNS 
Stomach 
Cervix 
Lung 
Pancreas 
Endometrial 
.Bladder 
Lymphoma 
• Modified from [8] with permission. 
ICD Code Number of Cases Mean kinship of Cases ( X 10-5 ) 
140. 486 3.82 
172. 499 3.32 
183. 435 3.02 
185. 2824 2.57 
153. 1638 2.08 
154. 736 2.04 
174.,175. 2525 2.02 
169. 941 1.95 
191., 192. 520 1.89 
151. 575 1.89 
180i" 588 1.87 
162. 1117 1.82 
157. 441 1.75 
182. 865 1.75 
188. 1182 1.68 
1K 721 1�7 
Table U. Demographic Data, Lod Score and Posterior Probability of Linkage By Kindred For 13 Kindreds in the Utah 
Data Set 
Kindred Number Average Age at dx Total Number Sampled Posterior Probability MaxLOD 
3364 
1771 
3137 
3012 
1764 
3355 
1763 
3106 
3157 
3348 
3006 
3247 
3343 
22 
14 
16 
4 
4 
3 
2 
2 
4 
7 
6 
3 
8 
60 
40 
44 
46 
38 
43 
24 
47 
57 
73 
60 
82 
44 
to expression of melanoma [11,16,17]. Originally, DNS seemed 
promising as a premalignant trait that would be useful in mapping 
and cloning a melanoma susceptibility locus. Much basic research 
has also been done on dysplastic nevus syndrome melanocytes, 
looking for a biochemical or molecular genetic lesion that would 
explain their propensity towards transformation to cancer [18].tt 
The usefulness of DNS as a clinical bridge to the melanoma 
susceptibility locus hinged on the ability to make accurate diag­
noses. In practice this means one should be able to take members of a 
family and divide them into two groups, affected and unaffected. 
Clinical, histopathologic, and cell biologic parameters had been 
suggested for those divisions. Unfortunately, as the case con­
trol studies cited above demonstrate, a fair proportion (5-14%) 
[10,14,15,19] of the general population has clinically atypical nevi 
and/or an increased nevus number. Some of the studies have sug­
gested a gradient of melanoma risk with increasing number of nevi. 
Studies of children have suggested that sun exposure also signifi­
cantly affects nevus number [20]. Finally the Utah data demonstrate 
a continuum of nevus phenotype, rather than a binary division. 
Histology has been suggested as a specific marker for genetic 
melanoma risk and for the diagnosis ofDNS [21]. However, histo­
logic analysis of nevi removed from controls shows that 5 -54% of 
the general population have histologically dysplastic nevi [19,22-
• Kraemer KH, Seetharam S, Waters HL, Seidman MM: Hereditary dys­
plastic nevus syndrome: abnormal UV mutagenic spectrum in association 
with increased melanoma susceptability (abstr). elin Res 36:664A, 1988 
t Yohn J, Robinson W, Norris 0: Melanocytes and nevus cells from 
dysplastic nevus syndrome patients do not have increased sensitivity to ultra­
violet.B radiation (abstr). elin Res 36:706A, 1988 
53 1.00 5.34 
30 1.00 4.24 
41 1.00 2.02 
9 0.98 1.01 
21 0.95 0.70 
22 0.83 0.08 
7 0.80 -0.01 
6 0.80 -0,01 
14 0.80 -0,01 
5 0.80 0.00 
26 0.58 -0.46 
9 0.57 -0.49 
17 0.33 -0.91 
24]. The studies with higher estimates have biopsied a higher num­
ber of unselected subjects. In our recent study of prevalence of 
dysplasia, random nevi were sampled from random members of our 
community and assessed by six separate pathologists [25]. Estimates 
of the prevalence of histologic dysplasia ranged from 9 to 32% with 
three of the six pathologists clustered in the 12 to 19% range. If 
over 10% of random nevi are judged to be dysplastic, clearly the 
proportion of persons bearing such dysplastic nevi is greater than 
10%. The histopathologic presence of an isolated dysplastic nevus is 
therefore not specific for melanoma risk. These clinical and histo­
logic diagnostic problems make genetic analysis of such a trait diffi­
cult. 
The inheritance patrern for DNS was said to be autosomal domi­
nant with a very high penetrance, based largely on the initial clinical 
observation of a few families [16]. Statistical evidence that dysplastic 
nevus syndrome behaves as an autosomal dominant trait has been 
difficult to generate, and hinged on the analysis of dysplastic nevus 
syndrome and melanoma as a combined trait [16,26]. Formal segre­
gation analysis of the dysplastic nevus syndrome (using clinical 
and/or histologic diagnostic criteria) has demonstrated over-segre­
gation [16,27]. That is, matings between affected and unaffected 
persons result in more than half their children being affected. Possi­
ble explanations of this over-segregation include a high phenocopy 
rate in the general population or misdiagnosis of the phenotype. A 
third explanation is that the trait is more complex, either involving 
more than one gene or involving more than one gene and an envi­
ronmental factor (polygenic or multifactorial inheritance). The sta­
tistical analysis of a pattern of inheritance or linkage is dependent on 
assumptions used in the genetic model, such as gene frequency, 
penetrance, and phenocopy rate, and is especially dependent on 
correct diagnosis. Any of these issues can drastically affect the results 
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Figure 1. Pedigrees of six kiDclreds in the Utah data set. Individuals with melanoma have solid circles. The age of individuals at the time of the exam, at the 
time of melanoma occurrence, or at death is given below the symbol. Individuals with DNA samples available are indicated with an asterisk. 
of genetic analysis. This may in part explain why different results 
have been reported. To avoid some of these problems, the Utah 
group chose to study the cutaneous melanoma phenotype only in 
studies looking for a susceptibility locus. 
GENE LOCATION 
Initial studies of "dysplastic nevus syndrome" and melanoma sug­
gested loose linkage to the Rh locus on chromosome lp [16]. A 
series of reports followed the initial linkage focusing first on dys­
plastic nevus syndrome and more recently on melanoma [11,28]. 
However, several groups have rejected linkage to lp for either mel­
anoma or for a combined melanoma and nevus phenotype trait 
[29-31]. 
Several other candidate regions have been suggested, largely 
based on cytogenetic studies of advanced tumors. Deletions in pre-
malignant tissue derived from dysplastic nevi suggested 9p as a 
po�sible site for a tumor-suppressor gene [32]. More recently the use 
pftnolecular probes involving conversion to homozygosity has re­
fined the ability to study small deleted areas of chromosomes. The 
chromosome 9p location has emerged as a consistently deleted re­
gion in early melanomas [33]. Recently, a woman with multiple 
melanomas, multiple atypical nevi, and multiple congenital anoma­
lies was identified as having a chromosomal abnormality. Cytoge­
netic chromosome analysis demonstrated a reciprocal translocation 
involving 5p and 9p, with the breakpoint being near 9p21 [34]. This 
supported 9p as a candidate for a melanoma risk gene. 
LINKAGE EVIDENCE TO 9p 
To avoid the problems with diagnosis and analysis of the dysplastic 
nevus syndrome as discussed above, we performed a linkage study 
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Figure 2. LOD score for various positious of the melanoma risk 
locus versus chromosome region on the short arm of chromosome 9 
by multipoint Unkage analysis [7]. Solid squares represents an age specific 
model that assumes melanoma is a rare autosomal dominant trait and allows 
sporadic cases of melanoma. The triangles represent an affected only model. 
which did not allow sporadic cases. For full details. see reference [7]. Re­
printed from [7] with permission. 
using invasive melanoma as the phenotype [7]. This requires a larger 
set of affected families than would a study of melanoma jointly with 
dysplastic nevus syndrome. We studied 13 families with multiple 
cases of melanoma (see Table U). Pedigrees of six of the Utah 
families are shown in Fig 1, with individuals affected with mela­
noma in solid symbols. Blood samples for DNA analysis were ob­
tained from all available family members and, in several cases, DNA 
was extracted from the pathologic tissue blocks of melanoma pa­
tients who were deceased. In all cases, diagnosis of melanoma was 
confirmed, usually by examination of tissue slides, but where these 
were not available by pathologic report. Only invasive cutaneous 
melanoma was included; lentigo maligna melanoma, ocular mela­
noma, congenital neurocutaneous melanoma, and melanoma in situ 
were not considered part of the affected phenotype. 
The linkage analysis used two probes from the region 9p21 near 
the interferon locus on chromosome 9p. Both probes are highly 
polymorphic in the general population, increasing their likelihood 
of providing information within each family. Linkage analysis tests 
the hypothesis that a particular polymorphism of one of the probes 
is co-inherited with the susceptibility to melanoma. If the mela­
noma susceptibility locus is in the same region of chromosome 9p as 
the probes, they will cosegregate within a family. The likelihood of 
a recombination between genetic loci varies, but is approximately 
1 % for every million base pairs. The statistical analysis of these data 
commonly uses a LOD score (which stands for logarithm of the 
odds) that allows this information to be pooled across families. A 
LCD score of 1 would correspond to odds of a physical association 
of the probe and the gene of 10: 1, a LCD score of 3 would corre­
spond to odds of 1 ,000: 1, and a LOD score of 0 would indicate even 
odds or a SO: SO chance. Negative LOD scores indicate the odds are 
against linkage. These LOD scores can be computed for different 
locations of the gene relative to the probes used in the study, thus 
generating a probability curve that the gene in question would lie in 
the given region. Such a graph is shown in Fig 2, showing data from 
10 of our Utah families and one Texas family [2]. As can be seen, the 
peak of the curve occurs at a LCD score of over 12, meaning the 
odds are 1012 to 1 in favor of a susceptibility locus for melanoma 
being in that region. 
Many assumptions are made in calculating odds that the mela­
noma gene lies in a specific region. These analyses include estimates 
of the gene frequency in the general population, the sporadic rate 
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(the rate of melanoma occurring from non-genetic origins), and a 
penetrance probability, which is the probability of expression of the 
disease in a gene-carrier. Various sets of estimates were used in 
performing these calculations, covering different assumptions of 
the genetic component of melanoma, representing the upper and 
lower curves in Fig 2 (for details see [7]). All analyses demonstrated 
strong evidence for linkage to a melanoma risk locus on chromo­
some 9p. 
Our families gave no evidence of genetic heterogeneity. That is, 
no kindreds appear to show evidence against linkage to the 9p locus . 
Several of our small kindreds have slightly negative LOD scores or 
LOD scores very near zero. However, linkage calculations on small 
data sets are confounded by the presumed possibility of sporadic 
melanoma, that is, melanoma occurring in someone without inher­
ited genetic susceptibility. Linkage studies of the 1 p locus do show 
statistical evidence of heterogeneity between the families [28]. 
Analysis of the Utah data show no evidence for linkage of mela­
noma susceptibility to chromosome 1p. Further studies involving 
linkage to large families will be required to assess heterogeneity. 
DISCUSSION 
Conclusive evidence from conversion to homozygosity in random 
melanoma tumors and from our linkage studies indicated that a 
major melanoma risk allele is located on chromosome 9p. The most 
reasonable model would suggest that this functions as a tumor sup­
pressor gene. We would predict that persons who carry this mela­
noma susceptibility gene have one abnormal copy; when the normal 
gene at 9p is either converted to the dysfunctional copy (conversion 
to homozygosity) or lost (conversion to hernizygosity) in peripheral 
tissue, a cancer develops. In patients who do not inherit any specific 
risk factor, it requires a genetic lesion in both copies, or loss of both 
copies (homozygous deletion). Recent studies have demonstrated 
conversion to homozygosity or homozygous deletion in this region 
of9p in both lung cancer and glioma tumors [35,36]. This suggests 
that this tumor suppressor gene may act in other tissues. This would 
be analogous to loss of function of the retinoblastoma gene resulting 
in both retinoblastoma and osteosarcoma, or to the many cancers 
associated with the p53 gene product. These results suggest that 
there is a major gene that controls growth of melanocytes and other 
cell types in this region. Specific studies of the effect of this gene 
will be possible once this gene is cloned. 
The relationship of the 9p melanoma risk locus to the atypical 
mole phenotype remains unclear. Previous studies on a subset of the 
families used in our linkage analysis demonstrated that total nevus 
density was inherited as an autosomal codorninant trait in families 
with multiple cases of melanoma [37]. This explained roughly 60% 
of the variation in nevus density in these kindreds, several of which 
were selected for multiple cases of atypical mole phenotype. Other 
families in our linkage study were selected only for the presence of 
multiple cases of melanoma. Analysis of this data set may shed light 
on the relationship between atypical mole syndrome and the 9p 
chromosomal melanoma risk allele. Preliminary assessment of these 
data suggest that there may be an increased number of nevi in family 
members who carry the melanoma risk allele.:!: 
Nevus phenotype appears to be influenced by various genetic and 
environmental factors. The most reasonable model may be a multi­
factorial model where nevus phenotype is determined by a major 
locus for melanoma risk, by other genetic loci (including those that 
affect skin color), and by environmental influences. 
We will learn much once the 9p melanoma susceptibility gene 
has been cloned. Although this appears to be an autosomal dominant 
locus that functions as a tumor-supyressor gene, the inference is 
based on indirect data. Cloning wi! allow direct tests for carrier 
status, thereby allowing calculations of the sex and age specific 
penetrance of melanoma within persons who carry the gene. This 
will also allow direct studies of the nevus phenotype of carriers and 
the interaction with environmental and other genetic risk factors. 
:j: Cannon-Albright LA, McWhorter WP, Meyer LJ, Goldgar DE, Lewis 
CM, Zone JJ, Skolnick MH: Penetrance and expressivity of the chromo­
some 9p melanoma susceptibility gene. Am] Human Genet 53:1715,1993 
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Perhaps most interesting however, will be studies of the molecular 
mechanism of this tumor suppressor gene with the unusual propen­
sity for homozygous deletion. 
Supported by a Veterans Administration award (LJM) and NIH Grants CA 
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